Oxford Nanopore Technologies plc (OXFYY)
OTCMKTS · Delayed Price · Currency is USD
7.10
+0.30 (4.42%)
At close: Dec 18, 2025
OXFYY Revenue
Oxford Nanopore Technologies had revenue of 105.60M GBP in the half year ending June 30, 2025, with 22.79% growth. This brings the company's revenue in the last twelve months to 204.69M, up 22.01% year-over-year. In the year 2024, Oxford Nanopore Technologies had annual revenue of 183.19M with 7.97% growth.
Revenue (ttm)
204.69M GBP
Revenue Growth
+22.01%
P/S Ratio
6.35
Revenue / Employee
154.48K GBP
Employees
1,325
Market Cap
1.78B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 183.19M | 13.52M | 7.97% |
| Dec 31, 2023 | 169.67M | -28.94M | -14.57% |
| Dec 31, 2022 | 198.60M | 64.94M | 48.59% |
| Dec 31, 2021 | 133.66M | 19.80M | 17.39% |
| Dec 31, 2020 | 113.86M | 61.80M | 118.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |